Skip to main content

Table 4 Probability that palivizumab is cost-effective for different WTP thresholds

From: A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Sub-group WTP threshold £20,000 WTP threshold £30,000
CHD 36.76% 51.52%
CLD 45.04% 60.06%
<29 wGA 45.02% 51.22%
29-32 wGA 30.44% 36.78%
33-35 wGA 2.8% 5.4%
  1. Abbreviations: CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age, WTP Willingness to pay.